100 related articles for article (PubMed ID: 33032941)
41. Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line.
Mriouah J; Boura C; Pinel S; Chretien AS; Fifre A; Merlin JL; Faivre B
Int J Oncol; 2010 Dec; 37(6):1555-63. PubMed ID: 21042725
[TBL] [Abstract][Full Text] [Related]
42. Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma.
Kumai T; Komatsuda H; Minami Y; Harabuchi Y
ORL J Otorhinolaryngol Relat Spec; 2020; 82(6):343-350. PubMed ID: 32882699
[TBL] [Abstract][Full Text] [Related]
43. Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer.
Pelster MS; Mott F; Lewin J
Laryngoscope; 2020 Apr; 130(4):E140-E143. PubMed ID: 31074845
[TBL] [Abstract][Full Text] [Related]
44. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results.
Balermpas P; Keller C; Hambek M; Wagenblast J; Seitz O; Rödel C; Weiss C
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e377-83. PubMed ID: 22414284
[TBL] [Abstract][Full Text] [Related]
45. PD-1 inhibition enters the frontline.
Killock D
Nat Rev Clin Oncol; 2020 Feb; 17(2):69. PubMed ID: 31729474
[No Abstract] [Full Text] [Related]
46. The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma.
da Costa AABA; Costa FD; Araújo DV; Camandaroba MPG; de Jesus VHF; Oliveira A; Alves ACF; Stecca C; Machado L; de Oliveira ACF; de Oliveira TB; Nicolau UR; de Lima VCC
Med Oncol; 2018 Nov; 36(1):8. PubMed ID: 30478503
[TBL] [Abstract][Full Text] [Related]
47. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
Huang LL; Shi YK
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852
[TBL] [Abstract][Full Text] [Related]
48. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.
Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T
Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692
[TBL] [Abstract][Full Text] [Related]
49. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
50. Cetuximab-Associated Pneumatosis Intestinalis.
Sherman E; Ramadas P; Lemke S
Am J Ther; 2019; 26(5):e609-e610. PubMed ID: 29965806
[No Abstract] [Full Text] [Related]
51. Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review.
Bonomo P; Loi M; Desideri I; Olmetto E; Delli Paoli C; Terziani F; Greto D; Mangoni M; Scoccianti S; Simontacchi G; Francolini G; Meattini I; Caini S; Livi L
Crit Rev Oncol Hematol; 2017 Dec; 120():98-110. PubMed ID: 29198343
[TBL] [Abstract][Full Text] [Related]
52. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study.
Heron DE; Rwigema JC; Gibson MK; Burton SA; Quinn AE; Ferris RL
Am J Clin Oncol; 2011 Apr; 34(2):165-72. PubMed ID: 20686406
[TBL] [Abstract][Full Text] [Related]
53. Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States.
Aggarwal H; Punekar RS; Li L; Carter GC; Walker MS
Health Qual Life Outcomes; 2020 Jun; 18(1):195. PubMed ID: 32571349
[TBL] [Abstract][Full Text] [Related]
54. Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma.
De Felice F; Vetrone L; Bulzonetti N; Caiazzo R; Marampon F; Musio D; Tombolini V
Med Oncol; 2019 Jun; 36(8):68. PubMed ID: 31190132
[TBL] [Abstract][Full Text] [Related]
55. Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins.
Boeckx C; Op de Beeck K; Wouters A; Deschoolmeester V; Limame R; Zwaenepoel K; Specenier P; Pauwels P; Vermorken JB; Peeters M; Van Camp G; Baay M; Lardon F
Cancer Lett; 2014 Nov; 354(2):365-77. PubMed ID: 25192874
[TBL] [Abstract][Full Text] [Related]
56. PD-1 immunotherapy for recurrent or metastatic HNSCC.
Ferris RL; Licitra L
Lancet; 2019 Nov; 394(10212):1882-1884. PubMed ID: 31679948
[No Abstract] [Full Text] [Related]
57. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
[TBL] [Abstract][Full Text] [Related]
58. Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab.
Ladányi A; Kapuvári B; Papp E; Tóth E; Lövey J; Horváth K; Gődény M; Remenár É
Head Neck; 2019 May; 41(5):1237-1245. PubMed ID: 30548478
[TBL] [Abstract][Full Text] [Related]
59. Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.
Araki D; Redman MW; Martins R; Eaton K; Baik C; Chow L; Goulart B; Lee S; Santana-Davila R; Liao J; Parvathaneni U; Laramore G; Futran N; Mendez E; Bhrany A; Rodriguez CP
Head Neck; 2016 Sep; 38(9):1318-23. PubMed ID: 27061333
[TBL] [Abstract][Full Text] [Related]
60. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F
Oncology; 2013; 84(4):251-4. PubMed ID: 23428719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
